Cytokinetics (CYTK) Tops Q4 EPS by 6c

Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Meridian Reports Unaudited Half-Yearly Financial Results for the Six Months Ended 30 June 2026
• Bernstein SocGen Group Downgrades Bridgestone Corp. (5108:JP) (BRDCY) to Market Perform